Kornimate/medical-research-clean huggingface dataset:
study investigating the effects of uvc beam and laser beam therapy according to standard therapy in patients with covid-19 diagnosis

Conditions: Covid19

Summary: clinical research study that evaluates the effect of turkish beam-selective uv developed by rd global araştirma geli̇şti̇rme sağlik i̇laç i̇nşaat yatirimlari a.ş. use into intravascular, intrapulmonary, intratracial, intrarespiratory area. bacteria, fungal and virus-based pathogens systematically to collect and evaluate specific clinical performance and safety data. this clinical research aims to investigate the effectiveness of the treatment group and control group mortality rates, intensive care hospitalization times, monitoring the virus load by pcr, and the treatment effectiveness of uvc application. this clinical research covers determining the treatment effectiveness and reliability of uvc application to patient groups, the details of which are determined in the protocol.

design prospective, parallel, multicentre, randomized controlled study ages between 40 and 75 years of age and positive symptoms such as fever, malaise, cough, and shortness of breath, or positive atypical pneumonia in ct findings or covid-19 (sars-cov-2) test in the intensive care unit, which is accepted as covid 19 infection and has been treated, patients will be treated with uvc radiation and laser beam treatment according to iku principles in addition to antimalarial therapy + antiviral therapy + anitibiotic therapy. standard treatment consisting of antimalarial therapy + antiviral therapy + antibiotic therapy will be applied to the control group. the dosage of the standard treatment consisting of antimalarial therapy + antiviral therapy + anitibiotic therapy, the number of days of treatment, and its active ingredient are indicated in the table.

Eligibility criteria:
inclusion criteria: * respiratory rate ≥ 30 * dyspnea and breathing difficulties findings * cases with oxygen saturation below 90% despite nasal oxygen support of 5 liters / minute and above * cases with partial oxygen pressure below 70 mmhg despite nasal oxygen support of 5 liters / minute and above * pao2 / fio2 \ 4 mmol / l bilateral infiltrations or multi-lobar involvement on chest x-ray or tomography * hypotension (systolic blood pressure \ 40 mmhg drop from usual skb, mean arterial pressure \<65 mmhg) * skin perfusion disorder organ dysfunction such as kidney function test, liver function test disorder, thrombocytopenia, confusion presence of immunosuppressive disease- presence of uncontrolled comorbidity with more than one feature * troponin height, arrhythmia * covid 19 test positivity exclusion criteria: * under 40 years old * pregnant women and those with suspected pregnancy * those with a history of anaphylaxis * those with known dna repair deficiencies: * those diagnosed with mental disorder, * puerperant women and lactating women
the effects of home-based graded repetitive arm supplementary program group on stroke.

Conditions: Stroke

Summary: graded repetitive arm supplementary program (grasp) is a self administrated, home-based rehabilitation program and has been incorporated in canadian stroke best practice recommendations. past studies indicated that the home-based grasp program could facilitate the motor function and motor recovery and prevent learned nonuse of affected upper limb of stroke patients. there is lacking of research and application of the home-based grasp program in taiwan. therefore, this study aims to explore the effects of the home-based grasp program, which is mainly executed in the form of group intervention, on the affected upper limb of stroke patients.


Eligibility criteria:
inclusion criteria: 1. age is above 20 years old. 2. onset of first stroke complicated with hemiplegia or hemiparesis. 3. the affected upper limb remains partially voluntary movements including lifting to chest level and holding for five seconds; slight flexion and extension of wrist and hand. 4. understanding and complying with two-steps commands. 5. understanding the content of trial and willing to sign informed consent. exclusion criteria: 1. complicating with other neurological disease. 2. having orthopedic diseases affecting the movements of upper limbs. 3. having symptoms of pain to affect the movements of upper limbs. 4. unstable vital sign or medical condition. 5. participating another rehabilitative or drug research meanwhile. 6. receiving botulinum toxin injection within three months.
a study to assess capecitabine (xeloda®) in patients with locally advanced or metastatic breast cancer

Conditions: Breast Cancer

Summary: this 2 arm study compared the efficacy and safety of label dose of capecitabine (xeloda®) to that of a lower dose of xeloda® plus docetaxel (taxotere®) in patients with locally advanced or metastatic breast cancer after failure of chemotherapy with an anthracycline. patients were randomized to receive either 1250 mg/m\^2 or 825 mg/m\^2 orally twice a day (po bid) on days 1-14 of each 3 week cycle, in combination with taxotere® 75 mg/m2 intravenous (iv) on day 1 of each 3 week cycle. the anticipated time on study treatment was until disease progression and the target sample size was 440 individuals.


Eligibility criteria:
inclusion criteria: * women \>=18 years of age; * \>=1 target lesion; * locally advanced or metastatic breast cancer; * demonstrated resistance to anthracycline; * \>=2 regimens of chemotherapy for advanced/metastatic disease. exclusion criteria: * previous treatment with xeloda, continuous 5-fluorouracil infusion, or other oral fluoropyrimidines; * previous treatment with paclitaxel or docetaxel for advanced/metastatic disease.
open label study of nvp+cbv treatment in women who have received sdnvp for the pmtct of hiv

Conditions: Acquired Immunodeficiency Syndrome

Summary: to determine the response to treatment with nvp, zdv and 3tc in hiv positive women, who previously received nvp for the prevention of mother to child transmission.

an open-label, single arm, multicentre study to determine the virologic and immunologic responsiveness of women, who previously received a regimen of nevirapine for the prevention of mtct, to a regimen of nevirapine and zdv+3tc treatment. as well as to evaluate the proportion of patients who fail this treatment at 24 and 48 weeks, and to evaluate the resistance profile of hiv isolates from patients who fail nevirapine and zdv+3tc treatment. study hypothesis: when a drug leading to selection of a resistant viral population is withdrawn the original wildtype virus, over time, becomes the predominant virus again. however, low frequency (below level of detection) of drug resistant viral sub-populations may be retained which could mean that the drug resistant variant might reappear rapidly should the same drug be reintroduced as part of combination therapy at a later stage.therefore this study is proposed to evaluate whether there is an impact of single dose nevirapine for the prevention of mtct on the subsequent response to a standard haart regimen that contains nevirapine. comparison(s): trial 1100.1090

Eligibility criteria:
inclusion criteria * hiv-1-infected non-pregnant women who received a nevirapine regimen, for the prevention of mother to child transmission, at least 12 months previously. * women of child-bearing potential must have a negative urine pregnancy test at the screening visit and ensure double barrier methods of contraception, which by definition will in all cases include the use of condoms, throughout the study period. * cd4 cell count \ 20,000 c/ml or any symptomatic individual (who stage 3) or the presence of any aids defining criteria. * documented hiv-1 positive status by a licensed hiv-1 elisa test. exclusion criteria * women who are pregnant or breastfeeding. * women with prior exposure to antiretroviral therapy, other than a nevirapine regimen for the prevention of mother to child transmission at least 12 months previously. * subjects who in the investigator's opinion are unlikely to complete the 48 week study period or unlikely to comply with the dosing schedule and protocol evaluations. * patients with a karnofsky performance status score \< 70. * subjects who fail to meet the hiv treatment criteria (cd4 and viral load) indicated above.
evaluating the effect of a novel web-based intervention to increase hiv testing in men who have sex with men

Conditions: HIV Testing

Summary: the proposed study is designed to develop and test the effectiveness of a novel web-based hiv intervention to motivate hiv testing among men who have sex with men (msm). the intervention arm includes the delivery of videos tailored to the reasons msm have for not getting tested for hiv, as well as hiv testing motivational messages sent via mobile-phone text messaging, e-mail or instant messaging. the intervention and assessments will be guided by the information-motivation-behavioral skills model, the health belief model and the stages of change theory. the control intervention will be a health promotion message (similar in content to other peruvian websites) with an invitation for free hiv testing. testing will be offered at the via libre and epicentro clinic, and at a mobile unit whose location will be determined based on participants' demand. the outcomes evaluated will be intention to get tested and actual hiv testing among msm of each of the trial arms.


Eligibility criteria:
inclusion criteria: * be 18 years of age or older, * be a man and report having had sex with a man within the last 12 months, * be a resident of metropolitan lima, peru, * have not been tested for hiv within the last 12 months, * have a valid e-mail address, * do not report being hiv positive. exclusion criteria: * do not meet the inclusion criteria specified above
study of the safety and efficacy of roxadustat in the treatment of heart failure with chronic kidney disease and anemia

Conditions: Heart Failure; Chronic Kidney Diseases; Anemia

Summary: the purpose of this study is to conduct a a cohort study to evaluate the efficacy and safety of the efficacy and safety of roxadustat for the treatment of anemia, quality of life and cardiac function in patients with heart failure and chronic kidney disease.

this is a cohort study in patients with anemia with heart failure complicated with chronic kidney disease, evaluating the the efficacy and safety of roxadustat. patients were divided into roxadustat group and control group according to whether roxadustat was used or not. the efficacy and safety of roxadustat for the treatment of anemia, quality of life and cardiac function in patients with heart failure and chronic kidney disease will be evaluated. the primary and secondary endpoints will be examined in subgroups determined by baseline variables reflecting demography, heart failure characteristics, diabetes status, kidney function, cardiac function, natriuretic peptide, dialysis, and additional co-morbidities, concomitant medications, and others.

Eligibility criteria:
inclusion criteria: 1. male or female, aged ≥18 years at the time of consent 2. weight between 45-160kg 3. definite diagnosis of heart failure: according to the diagnostic criteria for heart failure in "chinese heart failure diagnosis and treatment guidelines 2018" 4. egfr \<60ml/min/1.73 m\^2 by ckd-epi. 5. diagnosed anemia: male hemoglobin \<130 g/l, non-pregnant female hemoglobin \<120 g/l. 6. provision of signed informed consent prior to any study specific procedures. exclusion criteria: 1. acute or chronic active bleeding 6 months before enrollment. 2. anemias due to thalassemia, sickle cell anemia, pure red aplastic anemia, hemolytic anemia, ect. 3. thromboembolism requiring anticoagulation. 4. severe infection. 5. hepatic impairment aspartate transaminase \[ast\] or alanine transaminase \[alt\] \>3x the upper limit of normal \[uln\]; or total bilirubin \>2x uln at time of enrolment). 6. severe malnutrition. 7. women of child-bearing potential who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator or women who have a positive pregnancy test at enrolment or randomization or women who are breast-feeding. 8. patients who have received roxadustat treatment or are allergic to roxadustat.

Keywords: roxadustat anemia biomarkers
gv 1001 immunotherapy in patients with non-small cell lung cancer (nsclc)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: to examine the safety and efficacy of telomerase peptide vaccination ( stimulation of the immune system) in patients with nsclc after having been treated with conventional therapy with radiotherapy and docetaxel as a radiosensitizer.

survival in patients with locally advanced, inoperable nsclc may be improved if local control can be achieved with concurrent chemo radiotherapy .after completed standard chemo-and radiation therapy; the safety and efficacy of vaccination therapy will be measured as time to progression after treatment with gv1001. analysis of changes in t-cell subpopulations and cytokines in peripheral blood will be performed.

Eligibility criteria:
inclusion criteria: * patients with inoperable nsclc, disease stage iiia and stage iiib, who has received concurrent chemoradiotherapy( typically docetaxel 20 mg/m2 and 3d radiotherapy, 2gy x 30 within the last 4 weeks. * no sign of brain metastasis( excluded by mri of the brain) * male or female above the age of 18 years. * normal lab. values

Keywords: nsclc, vaccination inoperable nsclc stage iiia/b in good performance status
table to tablet (t2t): a novel intervention framework for children with speech sound disorders

Conditions: Speech Disorders

Summary: the primary aim of this study is to develop software as a tool in speech and language therapy for the treatment of children (portuguese and english) with phonologically based speech sound disorders (ssd). further, this project aims to test the effectiveness of this approach with two groups of preschool and school aged children with phonologically based ssd, with one group consisting of european portuguese (ep) speakers and one group of british english (be) speakers. performance across the two groups will be compared. the total duration of the project will be 30 month.

the table to tablet (t2t) project aims to develop software as a tool in speech and language therapy for the treatment of children (portuguese and english) with phonologically based speech sound disorders (ssd). further, this project aims to test the effectiveness of this approach with two groups of children aged between 3 years and 6 months and 6 years and 6 months with phonologically based speech sound disorders (ssd). one group consists of european portuguese (ep) speakers and one group of british english (be) speakers. each group should include 20 children with the referred criteria and the performance across the two groups will be compared. the total duration of the project will be 30 month (software development over the first 12 months and an intervention study during following 18 months). the t2t team includes 3 speech and language therapists and 3 engineers/researchers plus a designer that will develop the t2t material.

Eligibility criteria:
inclusion criteria: * diagnose of phonologically based speech and sound disorder; * portuguese as native language; * audition of 20 decibels (db) or lower in the frequencies 500, 1000, 2000 and 4000; * normal non-verbal ability (nviq) according to age; * receptive language skills within normal limits. exclusion criteria: * diagnose of childhood apraxia of speech; * structural or functional oral alterations

Keywords: speech sound disorders tabletop digital
efficacy and safety study of jnj-32729463 compared with moxifloxacin for the treatment of subjects requiring hospitalization for community-acquired bacterial pneumonia

Conditions: Community-Acquired Bacterial Pneumonia (CABP)

Summary: the purpose of this study is to determine the efficacy, safety and tolerability of jnj-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for community-acquired bacterial pneumonia (cabp).


Eligibility criteria:
inclusion criteria: * women of childbearing potential must agree to use an acceptable method of birth control * clinical diagnosis of community acquired bacterial pneumonia (cabp) * port score of ii or greater * able to generate an adequate sputum specimen * chest x-ray showing presence of new infiltrates in a lobar or multilobar distribution characteristic of bacterial pneumonia exclusion criteria: * history of tendon damage/disorders due to quinolone therapy * uncorrected hypokalemia * history of myasthenia gravis * intubated at the time of consent or subject is a candidate for enrollment into the open-label s. aureus arm and has been intubated greater than 12 hours prior to randomization * mild cabp with a port score of less than ii * viral, fungal, mycobacterial, or atypical pneumonia as a primary diagnosis * pneumonia suspected to be secondary to aspiration * primary, solitary lung abscess * healthcare-associated pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia * known bronchial obstruction or a history of postobstructive pneumonia. * primary lung cancer or another malignancy metastatic to the lungs * cystic fibrosis, known or suspected pneumocystis jiroveci (carinii) pneumonia, or known or suspected active tuberculosis * infection that necessitates the use of a concomitant antibacterial agent in addition to study medication * systemic antibiotics within the last 96 hours before randomization, with exceptions * hospitalized for greater than 72 hours for any reason 30 days before randomization (excluding the 24 hour period before enrollment). * history of a serious hypersensitivity reaction to any quinolone including moxifloxacin. * female and pregnant, breastfeeding, or may be pregnant. other protocol-specific eligibility criteria may apply

Keywords: community-acquired bacterial pneumonia cabp cap pneumonia pneumonia, bacterial bacterial infections anti-bacterial agents anti-infective agents lung disease, interstitial respiratory tract diseases respiratory tract infections community-acquired infections
a multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with primary sclerosing cholangitis.

Conditions: Primary Sclerosing Cholangitis

Summary: a multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with primary sclerosing cholangitis.

evaluation of efficacy, safety and tolerability of aldafermin in a phase 2b/3, randomized, double-blind, placebo-controlled, multi-center study in subjects with primary sclerosing cholangitis (alpine-psc)

Eligibility criteria:
inclusion criteria: 1. able and willing to give informed consent 2. confirmed diagnosis of psc based on either: 1. abnormal cholangiography consistent with psc as measured by mrcp with contrast 2. liver biopsy consistent with psc 3. lsm by vcte, indicative of at least f2 liver fibrosis stage 4. laboratory parameters: 1. tbl ≤2.5 mg/dl unless known for gilbert's syndrome 2. alt and alt \<5x uln 3. meld score ≤12 exclusion criteria: 1. clinically significant acute or chronic liver disease of an etiology other than psc 2. alternate causes of sclerosing cholangitis including igg4 related sclerosing cholangitis 3. subjects with moderate to severe hepatic impairment 4. subjects with moderate to severe renal impairment 5. placement of bile duct stent or percutaneous bile duct drain within 12 weeks of screening

Keywords: psc
covid-19 related lockdown effects on chronic diseases

Conditions: Chronic Coronary Syndrome; Heart Failure; AMD and Macular Edema; Chronic Respiratory Failure; Hemophilia; Malignant Hemopathy; Multiple Sclerosis; Horton's Disease

Summary: the containment associated with the vidoc-19 pandemic creates an unprecedented societal situation of physical and social isolation. our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. some messages about the additional risk/danger associated with taking certain drugs in the event of covid disease have been widely disseminated in the media since march 17, 2020, the date on which containment began in france. this is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ace inhibitors) and angiotensin ii receptor antagonists (arbs2). these four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, horton's disease; ace inhibitors/aras2: heart failure, chronic coronary artery disease). aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. the current difficulty of access to care due to travel restrictions (a theoretical limit in the context of french confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage covid-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. eight burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, horton's disease, amd, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, pah) haemophilia cohort) will study the health impact of the containment related to the covid-19 pandemic.


Eligibility criteria:
inclusion criteria: * patients with one of the following chronic diseases: chronic coronary syndrome, heart failure, multiple sclerosis, horton's disease, amd, malignant haemopathy, chronic respiratory failure (idiopathic fibrosis, pah, haemophilia) and already registered in one of the 8 burgundian registries/cohorts. exclusion criteria: * deceased patient, patient cannot be reached after \>3 telephone calls, patient or caregiver does not speak french to carry out telephone interviews
eeg characteristics in ect

Conditions: Electroconvulsive Therapy; Direct Current Electroencephalogram; Ketamine; Spreadind Depression

Summary: the investigators will be examining slow-wave characteristics in depressed patients receiving electroconvulsive therapy (ect) using direct current electroencephalogram (dceeg) by anesthesia induction agent.

this is a pilot project using dceeg to look at infra-slow waves in depressed patients receiving ect randomized to ketamine or methohexital where ketamine suppresses infra-slow waves. the rationale for this project is to identify biomarkers of treatment adequacy in ect, which could lead to decreased morbidity and mortality with the procedure and lessen the burden of depression in our patient population.

Eligibility criteria:
inclusion criteria: * structured clinical interview for dsm-5 will confirm diagnosis of mdd or bpd-depressed (with or without psychotic features * the clinical indications for ect including treatment resistance or a need for a rapid and definitive response; * hamilton depression rating scale 24-item (hdrs-24) \> 21; and * age range between 18 and 65 years of age. exclusion criteria: * defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness \> 5 minutes, epilepsy, alzheimer's disease); * other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder) * current drug or alcohol use disorder, except for nicotine and marijuana * adults unable to consent, pregnant women, prisoner * non-english speakers * patients that cannot tolerate methohexital and ketamine.